Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more here.

The upfront and near-term payment, backed by milestones that could take the total value of the licensing deal to around ... scalability," he said. Novo Nordisk and Septerna will jointly carry ...

Novo Nordisk said Wednesday that it will work ... a more convenient weight loss treatment to the market. Under the deal, Septerna, which specializes in making small-molecule drugs, is eligible ...

Novo Nordisk is making yet another bet on ... sets its molecules apart from the competition. Now, Septerna has the validation of a deal with Novo that is worth up to $2.2 billion across an upfront ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

The deal includes over $200 million in upfront and near-term payments to Septerna. The move is part of Novo Nordisk’s broader strategy to expand its presence in the highly competitive obesity ...

COPENHAGEN, May 14 (Reuters) - Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...